U.S. patent application number 12/779014 was filed with the patent office on 2010-09-23 for (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists.
This patent application is currently assigned to Richter Gedeon Vegyeszeti Gyar Rt.. Invention is credited to Eva Againe Csongor, Janos Galambos, Istvan Gyertyan, Bela Kiss, Istvan Laszlovszky, Judit Laszy, Katalin Nogradi, Katalin Saghy, Istvan Vago.
Application Number | 20100240640 12/779014 |
Document ID | / |
Family ID | 29287299 |
Filed Date | 2010-09-23 |
United States Patent
Application |
20100240640 |
Kind Code |
A1 |
Csongor; Eva Againe ; et
al. |
September 23, 2010 |
(THIO) Carbamoyl-Cyclohexane Derivatives as D3/D2 Receptor
Antagonists
Abstract
The present invention relates to new D3 and D2 dopamine receptor
subtype preferring ligands of formula (I): ##STR00001## wherein
R.sub.1 and R.sub.2 represent independently a substituent selected
from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R.sub.1 and
R.sub.2 may form a heterocyclic ring with the adjacent nitrogen
atom; X represents an oxygen or sulphur atom; n is an integer of
from 1 to 2, and/or geometric isomers and/or stereoisomers and/or
diastereomers and/or salts and/or hydrates and/or solvates thereof,
to the processes for producing the same, to pharmaceutical
compositions containing the same and to their use in therapy and/or
prevention of a condition which requires modulation of dopamine
receptors.
Inventors: |
Csongor; Eva Againe;
(Budapest, HU) ; Galambos; Janos; (Budapest,
HU) ; Nogradi; Katalin; (Budapest, HU) ; Vago;
Istvan; (Budapest, HU) ; Gyertyan; Istvan;
(Budapest, HU) ; Kiss; Bela; (Budapest, HU)
; Laszlovszky; Istvan; (Budapest, HU) ; Laszy;
Judit; (Nagykovacsi, HU) ; Saghy; Katalin;
(Budapest, HU) |
Correspondence
Address: |
FISH & RICHARDSON P.C.
P.O. BOX 1022
MINNEAPOLIS
MN
55440-1022
US
|
Assignee: |
Richter Gedeon Vegyeszeti Gyar
Rt.
Budapest
HU
|
Family ID: |
29287299 |
Appl. No.: |
12/779014 |
Filed: |
May 12, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11337275 |
Jan 20, 2006 |
7737142 |
|
|
12779014 |
|
|
|
|
PCT/HU2004/000056 |
May 21, 2004 |
|
|
|
11337275 |
|
|
|
|
Current U.S.
Class: |
514/218 ;
514/235.8; 514/252.11; 514/253.13; 514/254.01; 514/255.03; 540/575;
544/121; 544/357; 544/365; 544/372; 544/400 |
Current CPC
Class: |
A61P 25/14 20180101;
A61P 25/34 20180101; A61P 25/18 20180101; C07D 295/135 20130101;
A61P 15/00 20180101; A61P 25/24 20180101; A61P 25/32 20180101; C07D
223/04 20130101; A61P 25/30 20180101; A61P 25/22 20180101; C07D
295/215 20130101; A61P 25/20 20180101; C07D 243/08 20130101; A61P
25/28 20180101; A61P 15/10 20180101; A61P 25/16 20180101; A61P
25/36 20180101; A61P 25/00 20180101 |
Class at
Publication: |
514/218 ;
544/400; 514/255.03; 540/575; 544/372; 514/254.01; 544/357;
514/252.11; 544/121; 514/235.8; 544/365; 514/253.13 |
International
Class: |
A61K 31/495 20060101
A61K031/495; C07D 295/155 20060101 C07D295/155; C07D 243/08
20060101 C07D243/08; A61K 31/551 20060101 A61K031/551; C07D 403/12
20060101 C07D403/12; A61K 31/496 20060101 A61K031/496; C07D 413/12
20060101 C07D413/12; A61K 31/5377 20060101 A61K031/5377; C07D
401/12 20060101 C07D401/12; A61P 25/18 20060101 A61P025/18; A61P
25/30 20060101 A61P025/30; A61P 25/28 20060101 A61P025/28; A61P
25/00 20060101 A61P025/00; A61P 25/16 20060101 A61P025/16; A61P
25/22 20060101 A61P025/22; A61P 15/00 20060101 A61P015/00 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 4, 2003 |
HU |
P0302451 |
Claims
1. A compound of formula (I): ##STR00008## wherein R.sub.1 and
R.sub.2 represent independently a substituent selected from
hydrogen, alkyl, alkenyl, aryl, cycloalkyl, or aroyl, or R.sub.1
and R.sub.2 together with the adjacent nitrogen atom form a
heterocyclic ring; X represents an oxygen or sulphur atom; and n is
an integer of 1 to 2, and/or geometric isomers and/or stereoisomers
and/or diastereomers and/or salts and/or hydrates and/or solvates
thereof.
2. A compound of claim 1, wherein R.sub.1 and R.sub.2 represent
independently hydrogen, or a straight or branched C.sub.1-6 alkyl
optionally substituted with one or more C.sub.1-6 alkoxycarbonyl,
aryl, or (C.sub.1-6 alkoxycarbonyl)-C.sub.1-6 alkyl group, or
R.sub.1 and R.sub.2 together with the adjacent nitrogen atom form a
heterocyclic ring, which is a saturated or unsaturated optionally
substituted monocyclic or bicyclic ring, which may contain further
heteroatoms selected from O, N, or S, or C.sub.2-7 alkenyl with 1
to 3 double bonds, or a mono-, bi- or tricyclic aryl optionally
substituted with one or more C.sub.1-6 alkoxy, trifluoro C.sub.1-6
alkoxy, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkanoyl, aryl,
C.sub.1-6 alkylthio, halogen or cyano, or an optionally substituted
mono-, bi- or tricyclic cycloalkyl group, or aroyl group.
3. A compound of claim 2, wherein R.sub.1 and R.sub.2 represent
independently hydrogen, or a straight or branched C.sub.1-6 alkyl
optionally substituted with one or more C.sub.1-6 alkoxycarbonyl,
phenyl or (C.sub.1-6 alkoxycarbonyl)-C.sub.1-6 alkyl group or
R.sub.1 and R.sub.2 together with the adjacent nitrogen atom form a
hetero-monocyclic ring, which may be unsaturated or optionally
saturated by C.sub.1-6 alkyl or hydroxyl and which may contain
further heteroatoms selected from O or N, or C.sub.2-7 alkenyl with
1 double bond, or phenyl or naphthyl group optionally substituted
with one or more C.sub.1-6 alkoxy, trifluoro-C.sub.1-6 alkoxy,
C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkanoyl, aryl, C.sub.1-6
alkylthio, halogen or cyano, or cyclohexyl or adamantyl group, or
benzoyl group.
4. A compound of claim 3, wherein R.sub.1 and R.sub.2 represent
independently hydrogen, a straight or branched C.sub.1-6 alkyl
optionally substituted with C.sub.1-6 alkoxycarbonyl, or phenyl or
R.sub.1 and R.sub.2 together with the adjacent nitrogen atom form a
pyrrolidine, piperazine, piperidine or morpholine ring, which is
optionally substituted by C.sub.1-6 alkyl or a hydroxy group,
allyl, phenyl optionally substituted with one or more C.sub.1-6
alkoxy, cyano or C.sub.1-6 alkanoyl, or cyclohexyl; X represents
oxygen or sulphur; and n is 1.
5. A compound selected from
trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}--
3-methyl-urea,
trans-1-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-
-3-propyl-urea,
trans-1-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-
-3-isopropyl-urea,
trans-1-{-4-[2-[4-(2,3-dichlorophenyl)-hexahydro[1,4]diazepin-1-yl]-ethyl-
]-cyclohexyl}-3-ethyl-urea,
trans-1-{-4-[2-[4-(2,3-dichlorophenyl)-hexahydro[1,4]diazepin-1-yl]-ethyl-
]-cyclohexyl}-3,3-dimethyl-urea,
trans-N-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-
-pyrrolidine-1-carboxamide,
trans-N-{4-[2-[4-(2,3-dichlorophenyl)-hexahydro[1,4]diazepin-1-yl]-ethyl]-
-cyclohexyl}-pyrrolidine-1-carboxamide,
trans-1-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-
-3,3-diethyl-urea;
trans-1-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-
-3-ethyl-3-methyl-urea;
trans-1-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-
-3-methyl-3-propyl-urea;
trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}--
urea;
trans-N-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cycloh-
exyl}-piperazine-1-carboxamide;
trans-N-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl-]cyclohexyl}-
-4-methyl-piperazine-1-carboxamide;
trans-N-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-
-morpholine-4-carboxamide;
trans-N-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-
-piperidine-1-carboxamide;
trans-N-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-
-4-hydroxy-piperidine-1-carboxamide;
trans-1-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-
-3,3-dimethyl-urea,
trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}--
3-ethyl-urea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-(2-methoxy-phenyl)-urea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-(3-methoxy-phenyl)-urea,
trans-1-allyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyc-
lohexyl)-urea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-(2,4-dimethoxy-phenyl)-urea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-(2-ethoxy-phenyl)-urea,
trans-1-butyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyc-
lohexyl)-urea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-(4-trifluoromethoxy-phenyl)-urea,
trans-1-adamantan-1-yl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-e-
thyl}-cyclohexylyurea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl)-cyclohexyl}-
-3-(4-methylsulfanyl-phenyl)-urea,
trans-1-biphenyl-2-yl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-et-
hyl}-cyclohexylyurea
trans-2-[3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl)-cyclohex-
yl}-ureido]-3-methyl-butyric acid methyl ester,
trans-2-[3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethylycyclohexy-
l}-ureido]-benzoic acid methyl ester,
trans-1-(3-cyano-phenyl)-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-
-ethyl}-cyclohexyl)-urea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}cyclohexyl)--
3-(3,4,5-trimethoxy-phenyl)-urea,
trans-1-cyclohexyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl-
}-cyclohexyl)-urea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}cyclohexyl)--
3-propyl-urea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}cyclohexyl)--
3-phenyl-thiourea,
trans-1-adamantan-1-yl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-e-
thyl}-cyclohexyl)-thiourea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}cyclohexyl)--
3-ethoxycarbonyl-thiourea,
trans-1-tert-butyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl-
}-cyclohexyl)-thiourea,
trans-1-benzyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cy-
clohexylythiourea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-(2-methoxy-phenyl)-thiourea,
trans-1-butyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyc-
lohexyl)-thiourea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}cyclohexyl)--
3-propyl-thiourea,
trans-1-benzoyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-c-
yclohexyl)-thiourea,
trans-[3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl-
)-thioureido]-acetic acid ethyl ester
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-ethyl-thiourea,
trans-1-(4-{2-[4-(2,3-dichloro-phenylypiperazin-1-yl]-ethyl}-cyclohexyl)--
3-naphthalen-1-yl-thiourea,
trans-1-tert-butyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl-
}-cyclohexyl)-urea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-phenyl-urea,
trans-1-benzyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cy-
clohexylyurea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-(4-methoxy-phenyl)-urea,
trans-[3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl-
)-ureido]-acetic acid ethyl ester,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-(2-methoxy-phenyl)-urea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-(3-methoxy-phenyl)-urea,
trans-1-allyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyc-
lohexyl)-urea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-(2,4-dimethoxy-phenyl)-urea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-(2-ethoxy-phenyl)-urea,
trans-1-butyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyc-
lohexyl)-urea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-(4-trifluoromethoxy-phenyl)-urea,
trans-1-adamantan-1-yl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-e-
thyl}-cyclohexylyurea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-(4-methylthio-phenyl)-urea,
trans-1-biphenyl-2-yl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-et-
hyl}-cyclohexyl)-urea,
trans-2,3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexy-
l)-ureido]-3-methyl-butyric acid methyl ester,
trans-2-[3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl]-cyclohex-
yl)-ureido}-benzoic acid methyl ester,
trans-1-(3-cyano-phenyl)-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-
-ethyl}-cyclohexyl)-urea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}cyclohexyl)--
3-(3,4,5-trimethoxy-phenyl)-urea,
trans-1-cyclohexyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl-
}-cyclohexyl)-urea
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-phenyl-thiourea,
trans-1-adamantan-1-yl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-e-
thyl}-cyclohexylythiourea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-ethoxycarbonyl-thiourea,
trans-1-tert-butyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl-
}-cyclohexyl)-thiourea,
trans-1-benzyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cy-
clohexylythiourea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-(2-methoxy-phenyl)-thiourea,
trans-1-butyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyc-
lohexyl)-thiourea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-propyl-thiourea,
trans-1-benzoyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-c-
yclohexyl)-thiourea,
trans-[3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl-
)-thioureido]-acetic acid ethyl ester,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-ethyl-thiourea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-naphthalen-1-yl-thiourea,
trans-1-tert-butyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl-
}-cyclohexylyurea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-phenyl-urea,
trans-1-benzyl-3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cy-
clohexylyurea,
trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-
-3-(4-methoxy-phenyl)-urea,
trans-[3-(4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl-
)-ureido]acetic acid ethyl ester, and/or geometric isomers and/or
stereoisomers and/or diastereomers and/or salts and/or hydrates
and/or solvates thereof.
6. A process for preparing a compound of formula (I): ##STR00009##
wherein R.sub.1 and R.sub.2 represent independently a substituent
selected from hydrogen, alkyl, alkenyl, aryl, cycloalkyl, aroyl, or
R.sub.1 and R.sub.2 together with the adjacent nitrogen atom form a
heterocyclic ring; X represents an oxygen or sulphur atom; and n is
an integer of 1 to 2, and/or geometric isomers and/or stereoisomers
and/or diastereomers and/or salts and/or hydrates and/or solvates
thereof, which comprises: a) forming an amide bond between a
(thio)carbamoylchloride of formula (II): ##STR00010## wherein
R.sub.1, R.sub.2 and X are as defined above for formula (I), and an
amine of formula (III): ##STR00011## wherein n is as defined above
for formula (I), or derivatives thereof, or b) forming an amide
bond between the iso(thio)cyanate of formula (IV):
R.sub.1--N.dbd.C.dbd.X (IV) wherein R.sub.1 and X are as defined
above for the formula (I), and an amine of formula (III):
##STR00012## wherein n is as defined above for the formula (I), or
derivatives thereof, or c) transforming in situ an amine of formula
(III) to an iso(thio)cyanate derivative and reacting the latter
with an amine of formula (V): ##STR00013## wherein R.sub.1 and
R.sub.2 are as described above for the formula (I), or derivatives
thereof, and interconverting one compound (I) obtained by any of
method a) to c), wherein R.sub.1, R.sub.2, X and n are as defined
for compound (I) to a different compound of formula (I) wherein
R.sub.1, R.sub.2, X and n are as defined for compound (I); where
appropriate, separating the enantiomers and/or diastereomers,
and/or cis- and/or trans-isomers of compounds of formula (I), or
intermediates thereto wherein R.sub.1, R.sub.2, X and n are as
defined for compound (I) by conventional methods; and optionally
thereafter forming salts and/or hydrates and/or solvates.
7. The process of claim 6, wherein R.sub.1 and R.sub.2 represent
independently hydrogen, or a straight or branched C.sub.1-6 alkyl
optionally substituted with one or more C.sub.1-6 alkoxycarbonyl,
aryl, or (C.sub.1-6 alkoxycarbonyl)-C.sub.1-6 alkyl group, or
R.sub.1 and R.sub.2 together with the adjacent nitrogen atom form a
heterocyclic ring, which is a saturated or unsaturated optionally
substituted monocyclic or bicyclic ring, which may contain further
heteroatoms selected from O, N, or S, or C.sub.2-7 alkenyl with 1
to 3 double bond, or a mono-, bi- or tricyclic aryl optionally
substituted with one or more C.sub.1-6 alkoxy, trifluoro C.sub.1-6
alkoxy, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkanoyl, aryl,
C.sub.1-6 alkylthio, halogen or cyano, or an optionally substituted
mono-, bi- or tricyclic cycloalkyl group, or aroyl group.
8. The process of claim 7, wherein R.sub.1 and R.sub.2 represent
independently hydrogen, or a straight or branched C.sub.1-6 alkyl
optionally substituted with one or more C.sub.1-6 alkoxycarbonyl,
phenyl or (C.sub.1-6 alkoxycarbonyl)-C.sub.1-6 alkyl group or
R.sub.1 and R.sub.2 may form a heterocyclic ring with the adjacent
nitrogen atom, which may be unsaturated or saturated optionally by
C.sub.1-6 alkyl or hydroxy substituted monocyclic ring, which may
contain further heteroatoms selected from O or N, or C.sub.2-7
alkenyl with 1 double bond, or phenyl or naphthyl group optionally
substituted with one or more C.sub.1-6 alkoxy, trifluoro-C.sub.1-6
alkoxy, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkanoyl, aryl,
C.sub.1-6 alkylthio, halogen or cyano, or cyclohexyl or adamantyl
group, or benzoyl group.
9. The process of claim 8, wherein R.sub.1 and R.sub.2 represent
independently hydrogen, or a straight or branched C.sub.1-6 alkyl
optionally substituted with C.sub.1-6 alkoxycarbonyl, or phenyl or
R.sub.1 and R.sub.2 form with the adjacent nitrogen atom an
optionally by C.sub.1-6 alkyl or hydroxy substituted pyrrolidine,
piperazine, piperidine or morpholine ring, allyl, phenyl optionally
substituted with one or more C.sub.1-6 alkoxy, cyano or C.sub.1-6
alkanoyl, cyclohexyl; X represents oxygen or sulphur; and n is
1.
10. An amine of formula (III): ##STR00014## wherein n is 2, and/or
protected forms thereof and/or geometric isomers and/or
stereoisomers and/or diastereomers and/or salts and/or hydrates
and/or solvates thereof.
11. A pharmaceutical composition comprising a compound of formula
(I) ##STR00015## wherein R.sub.1 and R.sub.2 represent
independently a substituent selected from hydrogen, alkyl, alkenyl,
aryl, cycloalkyl, or aroyl, or R.sub.1 and R.sub.2 together with
the adjacent nitrogen atom form a heterocyclic ring; X represents
an oxygen or sulphur atom; and n is an integer of from 1 to 2,
and/or geometric isomers and/or stereoisomers and/or diastereomers
and/or physiologically acceptable salts and/or hydrates and/or
solvates thereof and one or more physiologically acceptable
carriers therefore.
12. The pharmaceutical composition of claim 11, wherein R.sub.1 and
R.sub.2 represent independently hydrogen, or a straight or branched
C.sub.1-6 alkyl optionally substituted with one or more C.sub.1-6
alkoxycarbonyl, aryl, or (C.sub.1-6 alkoxycarbonyl)-C.sub.1-6 alkyl
group, or R.sub.1 and R.sub.2 together with the adjacent nitrogen
atom form a heterocyclic ring, which is a saturated or unsaturated
optionally substituted monocyclic or bicyclic ring, which may
contain further heteroatoms selected from O, N, or S, or C.sub.2-7
alkenyl with 1 to 3 double bond, or a mono-, bi- or tricyclic aryl
optionally substituted with one or more C.sub.1-6 alkoxy,
trifluoro-C.sub.1-6 alkoxy, C.sub.1-6 alkoxycarbonyl, C.sub.1-6
alkanoyl, aryl, C.sub.1-6 alkylthio, halogen or cyano, or an
optionally substituted mono-, bi- or tricyclic cycloalkyl group, or
aroyl group.
13. The pharmaceutical composition of claim 12, wherein R.sub.1 and
R.sub.2 represent independently hydrogen, or a straight or branched
C.sub.1-6 alkyl optionally substituted with one or more C.sub.1-6
alkoxycarbonyl, phenyl or (C.sub.1-6 alkoxycarbonyl)-C.sub.1-6
alkyl group or R.sub.1 and R.sub.2 together with the adjacent
nitrogen atom form a hetero-monocyclic ring, which may be
unsaturated or optionally saturated by C.sub.1-6 alkyl or hydroxyl
and which may contain further heteroatoms selected from O or N, or
C.sub.2-7 alkenyl with 1 double bond, or phenyl or naphthyl group
optionally substituted with one or more C.sub.1-6 alkoxy,
trifluoro-C.sub.1-6 alkoxy, C.sub.1-6 alkoxycarbonyl, C.sub.1-6
alkanoyl, aryl, C.sub.1-6 alkylthio, halogen or cyano, or
cyclohexyl or adamantyl group, or benzoyl group.
14. The pharmaceutical composition of claim 13, wherein R.sub.1 and
R.sub.2 represent independently hydrogen, a straight or branched
C.sub.1-6 alkyl optionally substituted with C.sub.1-6
alkoxycarbonyl, or phenyl or R.sub.1 and R.sub.2 together with the
adjacent nitrogen atom form a pyrrolidine, piperazine, piperidine
or morpholine ring, which is optionally substituted by C.sub.1-6
alkyl or a hydroxy group, allyl, phenyl optionally substituted with
one or more C.sub.1-6 alkoxy, cyano or C.sub.1-6 alkanoyl, or
cyclohexyl; X represents oxygen or sulphur; and n is 1.
15. A method of treating and/or preventing a condition which
requires modulation of dopamine receptor(s) which comprises
administering to a subject in need thereof an effective amount of a
compound of formula (I) ##STR00016## wherein R.sub.1 and R.sub.2
represent independently a substituent selected from hydrogen,
alkyl, alkenyl, aryl, cycloalkyl, aroyl, or R.sub.1 and R.sub.2
together with the adjacent nitrogen atom form a heterocyclic ring;
X represents an oxygen or sulphur atom; and n is an integer of 1 to
2, and/or geometric isomers and/or stereoisomers and/or
diastereomers and/or physiologically acceptable salts and/or
hydrates and/or solvates thereof.
16. The method of claim 15, wherein R.sub.1 and R.sub.2 represent
independently hydrogen, or a straight or branched C.sub.1-6 alkyl
optionally substituted with one or more C.sub.1-6 alkoxycarbonyl,
aryl, or (C.sub.1-6 alkoxycarbonyl)-C.sub.1-6 alkyl group, or
R.sub.1 and R.sub.2 together with the adjacent nitrogen atom form a
heterocyclic ring, which is a saturated or unsaturated optionally
substituted monocyclic or bicyclic ring, which may contain further
heteroatoms selected from O, N, or S, or C.sub.2-7 alkenyl with 1
to 3 double bond, or a mono-, bi- or tricyclic aryl optionally
substituted with one or more C.sub.1-6 alkoxy, trifluoro C.sub.1-6
alkoxy, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkanoyl, aryl,
C.sub.1-6 alkylthio, halogen or cyano, or an optionally substituted
mono-, bi- or tricyclic cycloalkyl group, or aroyl group.
17. The method of claim 16, wherein R.sub.1 and R.sub.2 represent
independently hydrogen, or a straight or branched C.sub.1-6 alkyl
optionally substituted with one or more C.sub.1-6 alkoxycarbonyl,
phenyl or (C.sub.1-6 alkoxycarbonyl)-C.sub.1-6 alkyl group or
R.sub.1 and R.sub.2 together with the adjacent nitrogen atom form a
hetero-monocyclic ring, which may be unsaturated or optionally
saturated by C.sub.1-6 alkyl or hydroxyl and which may contain
further heteroatoms selected from O or N, or C.sub.2-7 alkenyl with
1 double bond, or phenyl or naphthyl group optionally substituted
with one or more C.sub.1-6 alkoxy, trifluoro-C.sub.1-6 alkoxy,
C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkanoyl, aryl, C.sub.1-6
alkylthio, halogen or cyano, or cyclohexyl or adamantyl group, or
benzoyl group.
18. The method of claim 17, wherein R.sub.1 and R.sub.2 represent
independently hydrogen, or a straight or branched C.sub.1-6 alkyl
optionally substituted with C.sub.1-6 alkoxycarbonyl, or phenyl or
R.sub.1 and R.sub.2 together with the adjacent nitrogen atom form a
pyrrolidine, piperazine, piperidine or morpholine ring, which is
optionally substituted by C.sub.1-6 alkyl or a hydroxy group,
allyl, phenyl optionally substituted with one or more C.sub.1-6
alkoxy, cyano or C.sub.1-6 alkanoyl, or cyclohexyl, X represents
oxygen or sulphur, and n is 1.
19. The method of any of claims 15 to 18, wherein the dopamine
receptor is a dopamine D.sub.3 and/or D.sub.2 receptor.
Description
[0001] This application is a continuation-in-part of International
Application No. PCT/HU2004/000056, filed May 21, 2004, which was
published in English as International Publication No. WO
2005/012266 and claims the benefit of Hungarian Patent Application
No. P0302451, filed Aug. 4, 2003, both of which are hereby
incorporated by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to new D.sub.3 and D.sub.2
dopamine receptor subtype preferring ligands of formula (I) and/or
geometric isomers and/or stereoisomers and/or diastereomers and/or
salts and/or hydrates and/or solvates thereof, to the processes for
producing the same, to pharmacological compositions containing the
same and to their use in therapy and/or prevention of a condition
which requires modulation of dopamine receptors.
DESCRIPTION OF THE PRIOR ART
[0003] Cyclohexane derivatives are described in patent application
WO 99/67206 useful in the therapy for the treatment of pain.
[0004] The compounds mentioned in the above publications are not
declared or even not suggested having activity on the dopamine
D.sub.3 and/or D.sub.2 receptors.
SUMMARY OF THE INVENTION
[0005] Surprisingly it was found that in contrast to the known
above mentioned structurally analogous compounds the new
derivatives of formula (I) of the present invention have high or
very high affinity for dopamine D.sub.3 receptors and moderate to
high affinity to dopamine D.sub.2 receptors always in such a
combination that the D.sub.3 affinity is 5 to 200 fold higher than
the D.sub.2 affinity. In addition, the compounds have even higher
selectivity over other receptors, such as alpha-1 receptors. The
dual (i.e. D.sub.3 and D.sub.2) receptor functional antagonism
coupled in the above mentioned particular proportion is especially
important as it allows the simultaneous manifestation of the
beneficial effects of modulation of both the D.sub.3 and D.sub.2
receptors, however, without the appearance of the known
disadvantages of each individual receptor action.
[0006] This type of new molecules belonging to the structure of
formula (I) will be referred further on in this application as
"D.sub.3/D.sub.2 ligands with D.sub.3 preference".
[0007] The invention relates to new cyclohexane derivatives having
(thio)carbamoyl side chain of formula (I):
##STR00002##
wherein
[0008] R.sub.1 and R.sub.2 represent independently a substituent
selected from hydrogen, alkyl, aryl, alkenyl, cycloalkyl, aroyl, or
R.sub.1 and R.sub.2 may form a heterocyclic ring with the adjacent
nitrogen atom;
[0009] X represents an oxygen or sulphur atom;
[0010] n is an integer of 1 to 2, and/or geometric isomers and/or
stereoisomers and/or diastereomers and/or salts and/or hydrates
and/or solvates thereof, to the processes for producing the same,
to pharmacological compositions containing the same and to their
use in therapy and/or prevention of pathological conditions which
require the modulation of dopamine receptors such as psychoses
(e.g. schizophrenia, schizo-affective disorders, etc.), drug (e.g.
alcohol, cocaine and nicotine, opioids, etc.) abuse, cognitive
impairment accompanying schizophrenia, mild-to-moderate cognitive
deficits, dementia, psychotic states associated with dementia,
eating disorders (e.g. bulimia nervosa, etc.), attention deficit
disorders, hyperactivity disorders in children, psychotic
depression, mania, paranoid and delusional disorders, dyskinetic
disorders (e.g. Parkinson's disease, neuroleptic induced
parkinsonism, tardive dyskinesias) anxiety, sexual dysfunction,
sleep disorders, emesis, aggression, autism.
DETAILED DESCRIPTION OF THE INVENTION
[0011] The invention relates to new cyclohexane derivatives having
(thio)carbamoyl side chain of formula (I):
##STR00003##
wherein
[0012] R.sub.1 and R.sub.2 represent independently a substituent
selected from hydrogen, alkyl, alkenyl, aryl, cycloalkyl, aroyl, or
R.sub.1 and R.sub.2 may form a heterocyclic ring with the adjacent
nitrogen atom;
[0013] X represents an oxygen or sulphur atom;
[0014] n is an integer of 1 to 2, and/or geometric isomers and/or
stereoisomers and/or diastereomers and/or salts and/or hydrates
and/or solvates thereof.
[0015] When R.sub.1 and/or R.sub.2 represent alkyl, the alkyl
moiety may contain 1 to 6 carbon atoms with straight or branched
chain optionally substituted with one or more C.sub.1-6
alkoxycarbonyl, aryl, preferably phenyl or (C.sub.1-6
alkoxycarbonyl)-C.sub.1-6 alkyl group.
[0016] R.sub.1 and R.sub.2 may form a heterocyclic ring with the
adjacent nitrogen atom, which may be saturated or unsaturated
optionally substituted monocyclic or bicyclic ring, which may
contain further heteroatoms selected from O, N, or S. The
heterocyclic ring is preferably pyrrolidine, piperazine, piperidine
or morpholine ring.
[0017] When R.sub.1 and/or R.sub.2 represent alkenyl, the alkenyl
moiety may have 2 to 7 carbon atoms and 1 to 3 double bonds.
[0018] When R.sub.1 and/or R.sub.2 represent aryl, the aryl moiety
may be selected from an optionally substituted mono-, bi- or
tricyclic aryl, such as phenyl, naphthyl, fluorenonyl, or
antraquinonyl group, preferably phenyl or naphthyl. The aryl moiety
may be substituted with one or more C.sub.1-6 alkoxy,
trifluoro-C.sub.1-6 alkoxy, C.sub.1-6 alkoxycarbonyl, C.sub.1-6
alkanoyl, aryl, C.sub.1-6 alkylthio, halogen or cyano. The aryl is
as defined above.
[0019] When R.sub.1 and/or R.sub.2 represent cycloalkyl, the
cycloalkyl moiety may be selected from an optionally substituted
mono-, bi- or tricyclic cycloalkyl group, such as cyclohexyl or
adamantyl.
[0020] When R.sub.1 and/or R.sub.2 represent aroyl the aryl moiety
therein is as defined above, preferably phenyl.
[0021] The invention relates also to the salts of compounds of
formula (I) formed with acids.
[0022] Both organic and inorganic acids can be used for the
formation of acid addition salts. Suitable inorganic acids can be
for example hydrochloric acid, sulfuric acid, nitric acid and
phosphoric acid. Representatives of monovalent organic acids can be
for example formic acid, acetic acid, propionic acid, and different
butyric acids, valeric acids and capric acids. Representatives of
bivalent organic acids can be for example oxalic acid, malonic
acid, maleic acid, fumaric acid and succinic acid. Other organic
acids can also be used, such as hydroxy acids for example citric
acid, tartaric acid, or aromatic carboxylic acids for example
benzoic acid or salicylic acid, as well as aliphatic and aromatic
sulfonic acids for example methanesulfonic acid, naphtalenesulfonic
acid and p-toluenesulfonic acid. Especially valuable group of the
acid addition salts is in which the acid component itself is
physiologically acceptable and does not have therapeutical effect
in the applied dose or it does not have unfavourable influence on
the effect of the active ingredient. These acid addition salts are
pharmaceutically acceptable acid addition salts. The reason why
acid addition salts, which do not belong to the pharmaceutically
acceptable acid addition salts belong to the present invention is,
that in given case they can be advantageous in the purification and
isolation of the desired compounds.
[0023] Solvates and/or hydrates of compounds of formula (I) are
also included within the scope of the invention.
[0024] The compounds of formula (I) exist in the form of cis and
trans isomers with respect to the configuration of the cyclohexane
ring. These and their mixtures are likewise within the scope of the
present invention. The compounds of the invention are preferably in
trans configuration.
[0025] Certain compounds of formula (I) when the compound contains
C.sub.2-7 alkenyl group can exist in the form of cis- and/or
trans-isomers. These are likewise within the scope of the present
invention including all such isomers and the mixtures thereof.
[0026] Certain compounds of formula (I) can exist as stereoisomers
and diastereomers, too. These and the mixtures thereof are likewise
within the scope of the present invention.
[0027] As the invention relates also to the salts of compounds of
formula (I) formed with acids, especially the salts formed with
pharmaceutically acceptable acids, the meaning of compound of
formula (I) is either the free base or the salt even if it is not
referred separately.
[0028] Preferred compounds of the invention are those compounds of
formula (I), wherein [0029] R.sub.1 and R.sub.2 represent
independently hydrogen, or [0030] C.sub.1-6 alkyl, with straight or
branched chain optionally substituted with one or more C.sub.1-6
alkoxycarbonyl, aryl, or (C.sub.1-6 alkoxycarbonyl)-C.sub.1-6 alkyl
group, or R.sub.1 and R.sub.2 may form a heterocyclic ring with the
adjacent nitrogen atom, which may be saturated or unsaturated
optionally substituted monocyclic or bicyclic ring, which may
contain further heteroatoms selected from O, N, or S, or [0031]
C.sub.2-7 alkenyl with 1 to 3 double bond, or [0032] a mono-, bi-
or tricyclic aryl optionally substituted with one or more C.sub.1-6
alkoxy, trifluoro C.sub.1-6 alkoxy, C.sub.1-6 alkoxycarbonyl,
C.sub.1-6 alkanoyl, aryl, C.sub.1-6 alkylthio, halogen or cyano, or
[0033] an optionally substituted mono-, bi- or tricyclic cycloalkyl
group, or aroyl group;
[0034] X represents oxygen or sulphur atom;
[0035] n is an integer of 1 to 2, and/or geometric isomers and/or
stereoisomers and/or diastereomers and/or salts and/or hydrates
and/or solvates thereof.
[0036] Particularly preferred compounds of the invention are those
compounds of formula (I), wherein [0037] R.sub.1 and R.sub.2
represent independently hydrogen, or [0038] C.sub.1-6 alkyl, with
straight or branched chain and optionally substituted with one or
more C.sub.1-6 alkoxycarbonyl, phenyl or (C.sub.1-6
alkoxycarbonyl)-C.sub.1-6 alkyl group or R.sub.1 and R.sub.2 may
form a heterocyclic ring with the adjacent nitrogen atom, which may
be saturated optionally by C.sub.1-6 alkyl or hydroxy substituted
monocyclic ring, which may contain further heteroatoms selected
from O or N, or [0039] C.sub.2-7 alkenyl with 1 double bond, or
[0040] phenyl or naphthyl group optionally substituted with one or
more C.sub.1-6 alkoxy, trifluoro-C.sub.1-6 alkoxy, C.sub.1-6
alkoxycarbonyl, C.sub.1-6 alkanoyl, aryl, C.sub.1-6 alkylthio,
halogen or cyano, or [0041] cyclohexyl or adamantyl group, or
[0042] benzoyl group;
[0043] X represents oxygen or sulphur atom;
[0044] n is an integer of 1 to 2, and/or geometric isomers and/or
stereoisomers and/or diastereomers and/or salts and/or hydrates
and/or solvates thereof.
[0045] The most prominent compounds of the invention are those
compounds of formula (I), wherein [0046] R.sub.1 and R.sub.2
represent independently hydrogen, or [0047] C.sub.1-6 alkyl with
straight or branched chain optionally substituted with C.sub.1-6
alkoxycarbonyl, or phenyl or R.sub.1 and R.sub.2 form with the
adjacent nitrogen atom an optionally by C.sub.1-6 alkyl or hydroxy
substituted pyrrolidine, piperazine, piperidine or morpholine ring;
[0048] allyl; [0049] phenyl optionally substituted with one or more
C.sub.1-6 alkoxy, cyano or C.sub.1-6 alkanoyl; [0050]
cyclohexyl;
[0051] X represents oxygen or sulphur;
[0052] n is 1, and/or geometric isomers and/or stereoisomers and/or
diastereomers and/or salts to and/or hydrates and/or solvates
thereof.
[0053] The invention also relates to the pharmaceutical
compositions containing the compounds of formula (I) as active
ingredient.
[0054] Further subject of the present invention is the
pharmaceutical manufacture of medicaments containing compounds of
formula (I), as well as the process of treatments and/or prevention
with these compounds, which means administering to a mammal to be
treated--including human--effective amount/amounts of compounds of
formula (I) of the present invention as such or as medicament.
[0055] The present invention also provides a process (Method A) for
preparing compounds of formula (I) by forming an amide bond between
a (thio)carbamoylchloride of formula (II)):
##STR00004##
[0056] wherein R.sub.1, R.sub.2 and X is as described above for the
formula (I);
and an amine of formula (III):
##STR00005##
[0057] wherein the meaning of n is as described above for the
formula (I), or derivatives thereof.
[0058] The amide bond formation may be carried out by known
methods, preferably by suspending or dissolving the appropriate
amine (III) or a salt thereof in a suitable solvent (e.g.
tetrahydrofurane, dimethylformamide or chlorinated hydrocarbons or
hydrocarbons) and reacting it with the appropriate
(thio)carbamoylchloride (II) in the presence of a base (e.g.
triethylamine). The reaction can be carried out advantageously
between -10.degree. C. and 60.degree. C. The reactions are followed
by thin layer chromatography. The necessary reaction time is about
6-60 h. The work-up of the reaction mixture can be carried out by
known methods. The products can be purified, e.g. by
crystallization or by column chromatography.
[0059] Another process (Method B) for preparing the compounds of
formula (I) by forming an amide bond between the iso(thio)cyanate
of formula (IV):
R.sub.1--N.dbd.C.dbd.X (IV)
wherein the meaning of R.sub.1 and X is as described above for the
formula (I), and an amine of formula (III):
##STR00006##
[0060] wherein the meaning of n is as described above for the
formula (I), or derivatives thereof.
[0061] The amide bond formation may be carried out by known
methods, preferably by suspending or dissolving the appropriate
amine (III) or a salt thereof in a suitable solvent (e.g.
tetrahydrofurane, dimethylformamide or chlorinated hydrocarbons or
hydrocarbons) and reacting it with the appropriate
iso(thio)cyanates (IV) if necessary in the presence of a base (e.g.
triethylamine). The reaction can be carried out advantageously
between 5.degree. C. and 50.degree. C. The reactions are followed
by thin layer chromatography. The necessary reaction time is about
6-10 h. The work-up of the reaction mixture can be carried out by
known methods. The products can be purified, e.g. by
crystallization or by column chromatography.
[0062] Method B may be carried out also by using automated parallel
synthesis.
[0063] Another process (Method C) for preparing compounds of
formula (I) is transforming in situ an amine of formula (III) to
iso(thio)cyanate derivative and reacting the latter with an amine
of formula (V):
##STR00007##
[0064] wherein R.sub.1 and R.sub.2 are as described above for the
formula (I), or derivatives thereof.
[0065] The above reaction may be carried out by known methods. The
transformation of amine (III) to iso(thio)cyanate derivative may be
carried out in situ in an aprotic solvent (e.g. tetrahydrofurane,
chlorinated hydrocarbons) by the use of an appropriate
(thio)carbonic acid derivative (e.g. phosgene, triphosgene,
thiophosgene) in the presence of a base (e.g. triethylamine),
advantageously between -5.degree. C. and room temperature. To the
thus obtained solution or suspension an appropriate amine of
formula (V), wherein R.sub.1 and R.sub.2 are as described above, is
added in the form of base or salt formed with organic or inorganic
acid. The necessary reaction time is between 2-24 hours. The
work-up of the reaction mixture can be carried out by known
methods. The products can be purified, e.g. by crystallization or
by column chromatography.
[0066] The obtained (thio)ureas of formula (I) can be transformed
into the salts thereof with acids and/or liberated the (thio)ureas
of formula (I) from the obtained acid addition salts by treatment
with a base, and/or the cis- and/or trans-isomers and/or the
stereoisomers and/or diastereomers can be separated and/or can be
transformed into hydrates and/or solvates thereof.
[0067] The (thio)carbamoylchlorides of formula (II) and
iso(thio)cyanates of formula (IV) and the amines of formula (V),
wherein R.sub.1, R.sub.2 and X are as defined above, are either
commercially available or can be synthesized by different known
methods.
[0068] The synthesis of amine of formula (III), wherein n=1 is
described e.g. in WO 03/029233 or in Bioorg. Med. Chem. Lett.; EN;
7; 18; 1997; 2403-2408.
[0069] The amines of formula (III), wherein n=2, are new compounds
and are also included within the scope of the present
invention.
[0070] The new amines of formula (III), wherein n=2 are synthesized
by conventional known methods mentioned above.
[0071] The compounds of formula (I) can also be prepared by
automated parallel synthesis.
[0072] The separation of cis- and trans isomers either of compounds
of formula (I) or of formula (III) or the protected derivatives of
the latter is carried out by conventional methods, e.g. by
chromatography and/or crystallization, or the cis and trans isomers
of formula (I) can be prepared from the pure cis or trans
precursor.
[0073] The compounds of formula (I) of the present invention, in
contrast to known antipsychotics, have been found to exhibit high
affinity for dopamine D.sub.3 receptors, less activity toward
D.sub.2 receptors and much less affinity to aderenergic alpha-1
receptors, and are expected to be useful in the treatment of
disease states and/or prevention the same in which dopamine D.sub.3
and/or D.sub.2 receptors are involved in the disease pathology and
thus their modulation is required.
[0074] Dysfunction of the dopaminergic neurotransmitter system is
involved in the pathology of several neuropsychiatric and
neurodegenerative disorders, such as schizophrenia, drug abuse and
Parkinson's disease, respectively. The effect of dopamine is
mediated via at least five distinct dopamine receptors belonging to
the D.sub.1-(D.sub.1, D.sub.5) or the D.sub.2-(D.sub.2, D.sub.3,
D.sub.4) families. D.sub.3 receptors have been shown to have
characteristic distribution in the cerebral dopaminergic systems.
Namely, high densities were found in certain limbic structures,
such as nucleus accumbens and islands of Calleja. Therefore,
preferential targeting of the D.sub.3 receptors may be a promising
approach for more selective modulation of dopaminergic functions
and consequently for successful therapeutic intervention in several
abnormalities, such as schizophrenia, emotional or cognitive
dysfunctions and addiction (Sokoloff, P. et al.: Nature, 1990, 347,
146; Schwartz, J. C. et al.: Clin. Neuropharmacol. 1993, 16, 295;
Levant, B.: Pharmacol. Rev. 1997, 49, 231), addiction (Pilla, C. et
al.: Nature 1999, 400, 371) and Parkinson's disease (Levant, B. et
al.: CNS Drugs 1999, 12, 391) or pain (Levant, B. et al.: Neurosci.
Lett. 2001, 303, 9).
[0075] The dopamine D.sub.2 receptors are widely distributed in the
brain and are known to be involved in numerous physiological
functions and pathological states. D.sub.2 antagonists are widely
used drugs as antipsychotics, for example. However, it is also well
known that massive antagonism of the D.sub.2 receptors leads to
unwanted side-effects such as extrapyramidal motor symptoms,
psychomotor sedation or cognitive disturbances. These side effects
seriously restrict the therapeutic utilization of D.sub.2
antagonist compounds. (Wong A. H. C. et al.: Neurosci. Biobehay.
Rev. 2003, 27, 269.).
[0076] The present invention provides novel compounds of formula
(I) and/or geometric isomers and/or stereoisomers and/or
diastereomers and/or salts and/or hydrates and/or solvates thereof
which have high (less than 10 nM) or very high (less than 1 nM)
affinity to dopamine D.sub.3 receptors and--simultaneously--have
moderate (between 50 and 200 nM) to high (between 1 and 10 nM)
affinity to D.sub.2 receptors always in such combination that the
D.sub.3 affinity is 5 to 200 fold higher than the D.sub.2
affinity.
[0077] In a further aspect of the present invention it provides a
method of treating conditions which require preferential modulation
of dopamine D.sub.3 and/or D.sub.2 receptors, for example psychoses
(e.g. schizophrenia, schizo-affective disorders), cognitive
impairment accompanying schizophrenia, mild-to-moderate cognitive
deficits, dementia, psychotic states associated with dementia,
psychotic depression, mania, paranoid and delusional disorders,
dyskinetic disorders such as Parkinson's disease, neuroleptic
induced parkinsonism, tardive dyskinesia, eating disorders (e.g.
bulimia nervosa), attention deficit disorders, hyperactivity
disorders in children, depression, anxiety, sexual dysfunction,
sleep disorders, emesis, aggression, autism and drug abuse, which
comprises administering to a subject in need thereof an effective
amount of a compound of formula (I) and/or geometric isomers and/or
stereoisomers and/or diastereomers and/or salts and/or hydrates
and/or solvates thereof.
[0078] The invention also provides the use of a compound of formula
(I) and/or geometric isomers and/or stereoisomers and/or
diastereomers and/or salts and/or hydrates and/or solvates thereof
in the manufacture of a medicament for the treatment of conditions
which require modulation of dopamine receptors especially that of
dopamine D.sub.3 and/or D.sub.2 receptors.
[0079] A preferred use for D.sub.3/D.sub.2 antagonists with D.sub.3
preference according to the present invention is in the treatment
of schizophrenia, schizo-affective disorders, cognitive impairment
accompanying schizophrenia, mild-to-moderate cognitive deficits,
dementia, psychotic states associated with dementia, psychotic
depression, mania, paranoid and delusional disorders, dyskinetic
disorders such as Parkinson's disease, neuroleptic induced
parkinsonism, depression, anxiety, drug abuse (e.g. cocaine
abuse).
[0080] The particular combination of the two receptor-actions
described above allows the simultaneous manifestation of the
beneficial actions of both the D.sub.3 antagonism (e.g. cognitive
enhancer effect, inhibition of extrapyramidal motor symptoms,
inhibitory action on drug abuse) and the D.sub.2 antagonism (e.g.
antipsychotic effect). Furthermore, the same combination
surprisingly results in cancelling out the disadvantageous features
of D.sub.2 antagonism (e.g. extrapyramidal symptoms, psychomotor
sedation, cognitive disturbances).
[0081] For use in medicine, the compounds of formula (I) of the
present invention and/or geometric isomers and/or stereoisomers
and/or diastereomers and/or physiologically acceptable salts and/or
hydrates and/or solvates thereof are usually administered as a
standard pharmaceutical composition. The present invention
therefore provides in a further aspect pharmaceutical compositions
comprising a new compound of formula (I) and/or geometric isomers
and/or stereoisomers and/or diastereomers and/or physiologically
acceptable salts and/or hydrates and/or solvates thereof and
physiologically acceptable carriers.
[0082] The compounds of formula (I) of the present invention and/or
geometric isomers and/or stereoisomers and/or diastereomers and/or
physiologically acceptable salts and/or hydrates and/or solvates
thereof may be administered by any convenient method, for example
by oral, parental, buccal, sublingual, nasal, rectal or transdermal
administration and the pharmaceutical compositions adapted
accordingly.
[0083] The compounds of formula (I) of the present invention and/or
geometric isomers and/or stereoisomers and/or diastereomers and/or
physiologically acceptable salts and/or hydrates and/or solvates
thereof which are active when given orally can be formulated as
liquids or solids, for example syrups, suspensions or emulsions,
tablets, capsules and lozenges.
[0084] A liquid formulation of the compounds of formula (I) of the
present invention and/or geometric isomers and/or stereoisomers
and/or diastereomers and/or physiologically acceptable salts and/or
hydrates and/or solvates thereof generally consists of a suspension
or solution of the compound of formula (I) and/or geometric isomers
and/or stereoisomers and/or diastereomers and/or salts and/or
hydrates and/or solvates thereof in a suitable liquid carrier(s)
for example an aqueous solvent, such as water, ethanol or
glycerine, or a non-aqueous solvent, such as polyethylene glycol or
an oil. The formulation may also contain a suspending agent,
preservative, flavouring or colouring agent.
[0085] A composition in the solid form of a tablet can be prepared
using any suitable pharmaceutical carrier(s) routinely used for
preparing solid formulations. Examples of such carriers include
magnesium stearate, starch, lactose, sucrose, cellulose etc.
[0086] A composition in the solid form of a capsule can be prepared
using routine encapsulation procedures. For example, pellets
containing the active ingredient can be prepared using standard
carriers and then filled into a hard gelatine capsule;
alternatively, a dispersion or suspension can be prepared using any
suitable pharmaceutical carrier(s), for example aqueous gums,
celluloses, silicates or oils and the dispersion or suspension then
filled into a soft gelatine capsule.
[0087] Typical parenteral compositions consist of a solution or
suspension of the compound of formula (I) of the present invention
and/or geometric isomers and/or stereoisomers and/or diastereomers
and/or physiologically acceptable salts and/or hydrates and/or
solvates thereof in a steril aqueous carrier or parenterally
acceptable oil, for example polyethylene glycol, polyvinyl
pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively,
the solution can be lyophilised and then reconstituted with a
suitable solvent just prior to administration.
[0088] Compositions of the present invention for nasal
administration containing a compound of formula (I) and/or
geometric isomers and/or stereoisomers and/or diastereomers and/or
physiologically acceptable salts and/or hydrates and/or solvates
thereof may conveniently be formulated as aerosols, drops, gels and
powders. Aerosol formulations of the present invention typically
comprise a solution or fine suspension of the compound of formula
(I) and/or geometric isomers and/or stereoisomers and/or
diastereomers and/or physiologically acceptable salts and/or
hydrates and/or solvates thereof in a physiologically acceptable
aqueous or non-aqueous solvent and are usually presented in a
single or multidose quantities in steril is form is a sealed
container, which can take the form of a cartridge or refill for use
with an atomising device. Alternatively, the sealed container may
be a unitary dispensing device, such as a single dose nasal inhaler
or an aerosol dispenser fitted with a metering valve which is
intended for disposal once the contents of the container have been
exhausted. Where the dosage form comprises an aerosol dispenser, it
will contain a propellant which can be a compressed gas, such as
compressed air or an organic propellant, such as a
fluorochlorohydrocarbon. The aerosol dosages form can also take the
form of a pump-atomiser. Compositions of the present invention
containing a compound of formula (I) and/or geometric isomers
and/or stereoisomers and/or diastereomers and/or physiologically
acceptable salts and/or hydrates and/or solvates thereof suitable
for buccal or sublingual administration include tablets, lozenges
and pastilles, wherein the active ingredient is formulated with a
carrier, such as sugar and acacia, tragacanth, or gelatine and
glycerin etc.
[0089] Compositions of the present invention containing a compound
of formula (I) and/or geometric isomers and/or stereoisomers and/or
diastereomers and/or physiologically acceptable salts and/or
hydrates and/or solvates thereof for rectal administration are
conveniently in the form of suppositories containing a conventional
suppository base, such as cocoa butter.
[0090] Compositions of the present invention containing a compound
of formula (I) and/or geometric isomers and/or stereoisomers and/or
diastereomers and/or physiologically acceptable salts and/or
hydrates and/or solvates thereof for transdermal administration
include ointments, gels and patches.
[0091] The compositions of the present invention containing a
compound of formula (I) and/or geometric isomers and/or
stereoisomers and/or diastereomers and/or physiologically
acceptable salts and/or hydrates and/or solvates thereof are
preferably in the unit dose form, such as tablet, capsule or
ampoule.
[0092] Each dosage unit of the present invention for oral
administration contains preferably from 1 to 250 mg of a compound
of formula (I) and/or geometric isomers and/or stereoisomers and/or
diastereomers and/or physiologically acceptable salts and/or
hydrates and/or solvates thereof calculated as a free base.
[0093] Each dosage unit of the present invention for parenteral
administration contains preferably from 0.1 to 2 mg of a compound
of formula (I) and/or geometric isomers and/or stereoisomers and/or
diastereomers and/or physiologically acceptable salts and/or
hydrates and/or solvates thereof calculated as a free base.
[0094] The physiologically acceptable compounds formula (I) of the
present invention and/or geometric isomers and/or stereoisomers
and/or diastereomers and/or physiologically acceptable salts and/or
hydrates and/or solvates thereof can normally be administered in a
daily dosage regimen (for an adult patient) of, for example, an
oral dose between 1 mg and 500 mg, preferably between 10 mg and 400
mg, e.g. between 10 mg and 250 mg or an intravenous, subcutaneous,
or intramuscular dose of between 0.1 mg and 100 mg, preferably
between 0.1 mg and 50 mg, e.g. between 1 and 25 mg of the compound
of formula (I) and/or geometric isomers and/or stereoisomers and/or
diastereomers and/or physiologically acceptable salts and/or
hydrates and/or solvates thereof calculated as the free base. The
compounds of the present invention can be administered 1 to 4 times
per day. The compounds of the present invention can suitably be
administered for a period of continuous therapy, for example for a
week or more.
[0095] Biological Test Methods
[0096] Receptor Binding Assays
1. D.sub.3 Receptor Binding
[0097] Binding assays were carried out on rat recombinant D.sub.3
receptors (expressed in Sf9 cells) according to the supplier
instruction (Packard BioScience, BioSignal Packard Inc. Cat. No.
6110139, Technical Data Sheet) using [.sup.3H]-spiperone (0.85 nM)
as ligand and haloperidol (10 .mu.M) for determination of
non-specific binding.
2. D.sub.2 Receptor Binding
[0098] D.sub.2 receptor binding assay was carried out as described
by Creese et al. (European Journal of Pharmacology 60:55-66, 1979)
on rat brain striatal membrane preparation using
[.sup.3H]-spiperone (0.6 nM) as ligand. The non-specific binding
was determined in the presence of 1 .mu.M (+)-butaclamol.
3. Alpha-1 Receptor Binding
[0099] Alpha-1 receptor binding study was performed according to
the method described by Greengrass and Bremmer (European Journal of
Pharmacology 55:323-326, 1979) on rat brain cortical membrane
preparation using [.sup.3H]-prasosin (0.5 nM) as ligand. The
non-specific binding was determined in the presence of 10 .mu.M
phentolamine.
[0100] D.sub.3 and D.sub.2 and alpha-1 receptor binding data of
selected compounds of the invention are listed in the Table
hereinbelow.
TABLE-US-00001 D3 D2 Alfa-1 Compound IC-50 (nM) IC-50 (nM) IC-50
(nM) 1 +++ ++ >200 2 ++++ ++ >200 4 ++++ ++ >200 5 ++++ ++
>200 6 ++++ ++ >200 7 +++ ++ >200 8 ++++ ++ >200 9 ++++
+++ >200 16 ++++ ++ >200 21 ++++ ++ >200 24 ++++ ++
>200 29 +++ ++ >200 31 ++++ ++ >200 32 ++++ ++ >200 33
++++ ++ >200 38 +++ ++ >200 42 ++++ ++ >200 44 ++++ ++
>200 45 ++++ ++ >200 47 ++++ ++ >200 48 ++++ ++ >200 49
++++ + >200 50 ++++ + >200 51 ++++ ++ >200 Haloperidol +
++ ++ Aripiprazole +++ ++ >200 Risperidone ++ ++ +++ Olanzapine
+ + ++ +: IC-50 is between 50 and 200 nM ++: IC-50 is between 10
and 50 nM +++: IC-50 is between 1 and 10 nM ++++: IC-50 is less
than 1 nM >200: IC-50 value is higher than 200 nM
[0101] The most prominent side effects of the first generation
antipsychotic compounds (e.g. chlorpromazine and haloperidol) are
the extrapyramidal symptoms such as pseudoparkinsonism and tardive
dyskinesia and the orthostatic hypotension. The former two are the
result of massive blockade of D.sub.2 receptors in the basal
ganglia whereas the latter is the consequence of antagonism of
alpha-1 receptors.
[0102] Compounds in the above Table are highly or very highly
potent ligands at D.sub.3 receptors (IC-50 values are less than 1
nM or between 1 and 10 nM, respectively) and moderately to highly
potent ligands at dopamine D.sub.2 receptors showing 5 to 200 fold
selectivity (selectivity: IC-50 for D.sub.2 divided by IC-50 for
D.sub.3) over D.sub.2 receptors. However, coupling the high or very
high D.sub.3 affinity to the moderate to high D.sub.2 affinity in
this particular proportion allows to preserve the beneficial (e.g.
antipsychotic) actions of a D.sub.2 antagonist while--at the same
time--impedes (by the D.sub.3 antagonism) the appearance of the
disadvantageous consequences of massive D.sub.2 receptor blockade
like extrapyramidal symptoms or cognitive disturbances. It is
therefore anticipated that no or greatly diminished adverse effects
related to D.sub.2 receptors will occur in the course of
therapeutical application of compounds of the present invention. In
addition, the compounds have very low or practically no affinity to
adrenergic alpha-1 receptors (IC-50 higher than 200 nM for each
compound) and thus have extremely high D.sub.3/alpha-1 selectivity
(ranging from several hundred-fold to several thousand fold). From
the very low or no affinity of the compounds to adrenergic alpha-1
receptors the lack of cardiovascular side effects (e.g. orthostatic
hypotension) is anticipated.
[0103] The invention is further illustrated by the following
non-limiting examples.
[0104] The structure of all intermediates and end products were
elucidated by IR, NMR and MS spectroscopy.
Example 1
1-(2,3-dichlorophenyl)-[1,4]diazepine
Starting Material
[0105] 2.25 g (10 mmol) 1-bromo-2,3-dichloro-benzene was dissolved
in dry toluene (50 ml), 2.3 (11 mmol) of
[1,4]diazepine-1-carboxylic acid tert-butylester was added followed
by 0.2 g BINAP (2,2-bis(diphenylphosphino)-1,1'-binaphtyl), 85 mg
tris(dibenzylideneacetone)dipalladium(0) and 1.2 g (12 mmol)
sodium-tert-butoxyde. The reaction mixture was refluxed for eight
hours and filtered. The organic layer was to washed with water,
dried and evaporated in vacuo. The residue was purified by
chromatography and deprotected at 10.degree. C. using 20 ml
ethylacetate saturated with gaseous hydrochloric acid, the
precipitate was filtered giving 2.1 g (yield: 75%) hydrochloride
salt of the title compound, melting at 182-3.degree. C.
Example 2
Trans-N-{4-[2-[4-(2,3-dichloro-phenyl)-hexahydro-[1,4]diazepin-1-yl]-ethyl-
]-cyclohexyl}-carbamic Acid Tert-Butylester
Intermediate
[0106] 0.7 g (2.5 mmol) of 1-(2,3-dichlorophenyl)-[1,4]diazepine
hydrochloride and 0.6 g (2.5 mmol) of
trans-2-{1-[4-(N-tert-butyloxycarbonyl)amino]cyclohexyl}-acetaldehyde
were dissolved in dichloroethane (35 ml), 0.35 ml (2.5 mmol)
triethylamine was added, then 0.79 g (3.7 mmol) sodium
triacetoxyborohydride was added portionswise and the reaction
mixture was stirred for 20 hours at ambient temperature, then 20%
potassium carbonate solution in water (20 ml) was added. The
organic layer was separated, dried and evaporated to dryness in
vacuo. The precipitate was recrystallized from acetonitrile to give
the title compound 1.0 g (yield: 85.8%), m.p.: 95-8.degree. C.
Example 3
Trans-4-[2-[4-(2,3-dichloro-phenyl)-hexahydro-[1,4]diazepin-1-yl]-ethyl]-c-
yclohexylamine
Intermediate
[0107] 0.93 g (2.1 mmol)
trans-N-{-4-[2-[4-(2,3-dichloro-phenyl)-hexahydro-[1,4]diazepin-1-yl]ethy-
l]-cyclohexyl}-carbamic acid tert-butylester was deprotected at
10.degree. C. using 15 ml ethylacetate saturated with gaseous
hydrochloric acid, after 4 hours the precipitate was filtered
giving 0.91 g (yield: 98%) dihydrochloride salt of the title
compound, melting at 260-6.degree. C.
Method A
Trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3-
,3-dimethyl-urea
Compound 1
[0108] 1.39 g (3 mmol)
trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]ethyl}-cyclohexyl-amine
trihydrochloride was suspended in dichloromethane (100 ml),
triethylamine (2.1 ml, 15 mmol) was added followed by 0.30 ml (3.3
mmol) N,N-dimethylcarbamoylchloride. The reaction mixture was
stirred for 48 hours at room temperature, filtered. The filtrate
was washed with water (2.times.20 ml), dried and evaporated in
vacuo. Recrystallizing from methanol gave the title compound (0.83
g, 65%), melting at 212-4.degree. C.
Method B
Trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3-
-ethyl-urea
Compound 2
[0109] 0.56 g (1.2 mmol)
trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]ethyl}-cyclohexyl-amine
was dissolved in dry dichloromethane (20 ml), ethylisocyanate (0.1
ml, 1.3 mmol) was added and the reaction mixture was stirred at
room temperature for 4 hours. The solvent was removed in vacuo. The
residue was stirred with water, the precipitate was filtered,
giving the title compound (0.33 g, 65%). Melting point:
235-8.degree. C.
Method C
Trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3-
,3-dimethyl-urea
Compound 1
[0110] 0.56 g (1.2 mmol)
trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-cyclohexyl-amin-
e trihydrochloride was suspended in dry dichloromethane (50 ml),
triethylamine 0.77 ml, 6 mmol) was added and 0.13 g (0.44 mmol)
triphosgene dissolved in dichloromethane was dropped in. After one
hour stirring at room temperature dimetilamine hydrochloride (0.49
g, 6 mmol) followed by triethylamine (0.84 ml, 6 mmol) was added
and the stirring was continued for 20 hours. The mixture was
filtered, the filtrate washed with water, dried and evaporated in
vacuo. Recrystallizing the product from methanol gave the title
compound (0.27 g, 52%). Melting point: 212-4.degree. C.
[0111] Applying one of the above procedures the following compounds
were prepared: [0112]
trans-1-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]ethyl]-cyclohexyl}--
3-methyl-urea (compound 3), melting point: 210-4.degree. C.; [0113]
trans-1-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-
-3-propyl-urea (compound 4), melting point: 218-20.degree. C.;
[0114]
trans-1-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-
-3-isopropyl-urea (compound 5), melting point: 227-30.degree. C.;
[0115]
trans-1-{4-[2-[4-(2,3-dichlorophenyl)-hexahydro[1,4]diazepin-1-yl-]ethyl]-
-cyclohexyl}-3-ethyl-urea (compound 6), melting point:
115-8.degree. C.; [0116]
trans-1-{-4-[2-[4-(2,3-dichlorophenyl)-hexahydro[1,4]diazepin-1-yl-
]-ethyl]-cyclohexyl}-3,3-dimethyl-urea (compound 7), melting point:
168-72.degree. C.; [0117]
trans-N-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}--
pyrrolidine-1-carboxamide (compound 8), melting point:
201-3.degree. C.; [0118]
trans-N-{-4-[2-[4-(2,3-dichlorophenyl)-hexahydro[1,4]diazepin-1-yl-
]-ethyl]-cyclohexyl}-pyrrolidine-1-carboxamide (compound 9); [0119]
trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}--
3,3-diethyl-urea (compound 10), melting point: 171-3.degree. C.;
[0120]
trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}--
3-ethyl-3-methyl-urea (compound 11), melting point: 195-8.degree.
C.; [0121]
trans-1-{4-[2-[4-(2,3-dichlorophenylypiperazin-1-yl]-ethyl]-cycloh-
exyl}-3-methyl-3-propyl-urea (compound 12), melting point:
137-9.degree. C.; [0122]
trans-1-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-
-urea (compound 13), melting point: 215-7.degree. C.; [0123]
trans-N-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl-]ethyl]-cyclohexyl}-
-piperazine-1-carboxamide (compound 14), melting point:
293-6.degree. C.; [0124]
trans-N-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cycl-
ohexyl}-4-methyl-piperazine-1-carboxamide (compound 15), melting
point: 166-8.degree. C.; [0125]
trans-N-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-
-morpholine-4-carboxamide (compound 16), melting point:
201-3.degree. C.; [0126]
trans-N-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclo-
hexyl}-piperidine-1-carboxamide (compound 17), melting point:
188-90.degree. C.; [0127]
trans-N-{-4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-
-4-hydroxy-piperidine-1-carboxamide (compound 18), melting point:
178-80.degree. C.
Automated Parallel Synthesis (General Procedure)
[0128] 0.1 mmol of
trans-4-{2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl}-cyclohexylamin-
e was dissolved in 1 ml of dichloromethane, and 0.1 mmol of the
appropriate isocyanate or isothiocyanate compound was added. The
mixture was vigorously shaken for 12 hours. The solvent was
evaporated in vacuo. 1 ml of n-hexane was added to the remaining
solid and the mixture was vigorously shaken for 20 minutes. The
solvent was decanted from the solid residue, and the solid was
dried in vacuo.
[0129] Applying the above procedures the following compounds were
prepared:
TABLE-US-00002 Purity (HPLC compound mol weight k' Area %) Iupac 19
505.49 5,768 99.4 trans-1-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-3-(2- methoxy-phenyl)-urea 20
505.49 5,807 95.59 trans-1-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-3-(3- methoxy-phenyl)-urea 21
439.43 4,816 96.25 trans-1-Allyl-3-(4-{2-[4-(2,3-dichloro-
phenyl)-piperazin-1-yl]-ethyl}- cyclohexyl)-urea 22 535.52 5,901
99.52 trans-1-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-3-(2,4- dimethoxy-phenyl)-urea
23 519.52 6,092 98.37 trans-1-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-3-(2- ethoxy-phenyl)-urea 24
455.48 6,123 95.02 trans-1-Butyl-3-(4-{2-[4-(2,3-dichloro-
phenyl)-piperazin-1-yl]-ethyl}- cyclohexyl)-urea 25 559.46 6,619
94.62 trans-1-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-3-(4-
trifluoromethoxy-phenyl)-urea 26 533.59 6,324 99.43
trans-1-Adamantan-1-yl-3-(4-{2-[4-(2,3-
dichloro-phenyl)-piperazin-1-yl]-ethyl}- cyclohexyl)-urea 27 521.56
5,976 88.03 trans-1-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-3-(4-
methylsulfanyl-phenyl)-urea 28 551.56 6,441 85.42
trans-1-Biphenyl-2-yl-3-(4-{2-[4-(2,3-
dichloro-phenyl)-piperazin-1-yl]-ethyl}- cyclohexyl)-urea 29 513.51
5,354 99.3 trans-2-[3-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-ureido]- 3-methyl-butyric acid
methyl ester 30 533.50 6,161 96.32
trans-2-[3-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)- ureido]-benzoic acid methyl
ester 31 500.48 5,704 93.41
trans-1-(3-Cyano-phenyl)-3-(4-{2-[4-(2,3-
dichloro-phenyl)-piperazin-1-yl]-ethyl}- cyclohexyl)-urea 32 565.55
5,694 93.74 trans-1-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}cyclohexyl)-3-(3,4,5- trimethoxy-phenyl)-urea
33 481.51 5,591 99 trans-1-Cyclohexyl-3-(4-{2-[4-(2,3-
dichloro-phenyl)-piperazin-1-yl]-ethyl}- cyclohexyl)-urea 34 441.45
5,121 96.93 trans-1-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-3- propyl-urea 35 491.53 5,689
98.53 trans-1-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-3- phenyl-thiourea 36 549.65
6,852 95.94 trans-1-Adamantan-1-yl-3-(4-{2-[4-(2,3-
dichloro-phenyl)-piperazin-1-yl]-ethyl}- cyclohexyl)-thiourea 37
487.50 5,951 99 trans-1-(4-{2-[4-(2,3-dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-3- ethoxycarbonyl-thiourea 38
471.54 5,634 97.03 trans-1-tert-Butyl-3-(4-{2-[4-(2,3-
dichloro-phenyl)-piperazin-1-yl]-ethyl}- cyclohexyl)-thiourea 39
505.56 5,909 99 trans-1-Benzyl-3-(4-{2-[4-(2,3-dichloro-
phenyl)-piperazin-1-yl]-ethyl}- cyclohexyl)-thiourea 40 521.56 5,77
94.24 trans-1-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-3-(2- methoxy-phenyl)-thiourea
41 471.54 5,786 99 trans-1-Butyl-3-(4-{2-[4-(2,3-dichloro-
phenyl)-piperazin-1-yl]-ethyl}- cyclohexyl)-thiourea 42 457.51
5,387 96.79 trans-1-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-3- propyl-thiourea 43 519.54
6,459 97.68 trans-1-Benzoyl-3-(4-{2-[4-(2,3-dichloro-
phenyl)-piperazin-1-yl]-ethyl}- cyclohexyl)-thiourea 44 501.52
5,382 96.17 trans-[3-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)- thioureido]-acetic acid ethyl
ester 45 443.49 5,007 99 trans-1-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-3-ethyl- thiourea 46 541.59
6,401 96.26 trans-1-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-3- naphthalen-1-yl-thiourea 47
455.48 5,143 94.98 trans-1-tert-Butyl-3-(4-{2-[4-(2,3-
dichloro-phenyl)-piperazin-1-yl]-ethyl}- cyclohexyl)-urea 48 475.47
5,481 95.69 trans-1-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-3- phenyl-urea 49 489.49 5,491
94.42 trans-1-Benzyl-3-(4-{2-[4-(2,3-dichloro-
phenyl)-piperazin-1-yl]-ethyl}- cyclohexyl)-urea 50 505.49 5,666
90.78 trans-1-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-3-(4- methoxy-phenyl)-urea 51
485.46 4,754 97.78 trans-[3-(4-{2-[4-(2,3-Dichloro-phenyl)-
piperazin-1-yl]-ethyl}-cyclohexyl)-ureido]- acetic acid ethyl
ester
[0130] The LC/MS analysis were performed using an HP 1100 binary
gradient system, controlled by ChemStation software. HP diode array
detector was used to acquire UV spectra at .lamda.=210 nm.
Analytical chromatographic experiments were made on Discovery
C.sub.1-6-Amide, 5 cm.times.4.6 mm.times.5 .mu.m column with a flow
rate of 0.8 ml/min for qualification (purity, capacity factor). All
experiments were performed using HP MSD single quadruple mass
spectrometer equipped with an electrospray ionisation source to
determine the molecular mass.
[k'=t.sub.R-t.sub.0/t.sub.0 t.sub.R=retention time [0131]
t.sub.0=eluent retention time] [0132] k'=capacity factor
[0133] The A eluent was water containing 0.1% TFA (Sigma, Germany),
the B eluent was 95% acetonitrile (Merck, Germany) containing 0.1%
TFA and 5% A eluent. Gradient elution was used, starting with 100%
A eluent and processing to 100% B eluent over a period of 15
minutes.
TABLE-US-00003 Pharmaceutical formulations a) Intravenous injection
Compound of formula (I) 1-40 mg Buffer to pH ca 7
Solvent/complexing agent to 100 ml b) Bolus injenction Compound of
formula (I) 1-40 mg Buffer to pH ca 7 Co-solvent to 5 ml Buffer:
suitable buffers include citrate, phosphate, sodium
hydroxide/hydrochloric acid. Solvent: typically water but may also
include cyclodextrins (1-100 mg) and co-solvents, such as propylene
glycol, polyethylene glycol and alcohol. c) Tablet Compound of
formula (I) 1-40 mg Diluent/Filter(may also include cyclodextrins)
50-250 mg Binder 5-25 mg Disintegrant (may also include
cyclodextrins) 5-50 mg Lubricant 1-5 mg Cyclodextrin 1-100 mg
Diluent: e.g. mycrocrystalline cellulose, lactose starch. Binder:
e.g. polyvinylpyrrolidone, hydroxypropylmethylcellulose.
Disintegrant: e.g. sodium starch glycolate, crospovidone.
Lubricant: e.g. magnesium stearate, sodium stearyl fumarate d) Oral
suspension Compound of formula (I) 1-40 mg Suspending agent 0.1-10
mg Diluent 20-60 mg Preservative 0.01-1.0 mg Buffer to pH ca 5-8
Co-solvent 0-40 mg Flavour 0.01-1.0 mg Colourant 0.001-0.1 mg
Suspending agent: e.g. xanthan gum, mycrocrystalline cellulose.
Diluent: e.g. sorbitol solution, tipically water. Preservative:
e.g. sodium benzoate. Buffer: e.g. citrate. Co-solvent: e.g.
alcohol, propylene glycol, polyethylene glycol, cyclodextrin.
* * * * *